Enfortumab vedotin, a novel targeted-antibody treatment has produced responses in nearly half of patients with advanced urothelial cancer
A single arm, phase II clinical trial of 125 patients has shown treatment with Enfortumab vedotin, an agent targeting nectin-4, a protein found in 97% of urothelial cancers, has produced responses in ...
read article